Filing Details

Accession Number:
0001104659-19-050627
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-18 21:37:41
Reporting Period:
2019-09-16
Accepted Time:
2019-09-18 21:37:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1709401 Rubius Therapeutics Inc. RUBY Biological Products, (No Disgnostic Substances) (2836) 042688109
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1746845 L. Christopher Carpenter C/O Rubius Therapeutics, Inc.
399 Binney Street, Suite 300
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-16 36,123 $2.87 70,966 No 4 M Direct
Common Stock Disposition 2019-09-16 36,123 $10.13 34,843 No 4 S Direct
Common Stock Acquisiton 2019-09-17 11,877 $2.87 46,720 No 4 M Direct
Common Stock Disposition 2019-09-17 11,877 $10.05 34,843 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-09-16 36,123 $0.00 36,123 $2.87
Common Stock Stock Option (Right to Buy) Disposition 2019-09-17 11,877 $0.00 11,877 $2.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
583,034 2027-10-24 No 4 M Direct
571,157 2027-10-24 No 4 M Direct
Footnotes
  1. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.31, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.21, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. 25% of this option shall vest on September 18, 2018, then in 12 equal quarterly installments thereafter.